icon-    folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections (CROI)
February 13-16, 2017, Seattle WA
Back grey_arrow_rt.gif
 
 
 
CROI 2017 Summary Report - A lot Going On - good Conference with Lots of New Information - New HIV Drugs, Aging/Comorbidities, Cure & PrEP, Fatty Liver/HCV-HBV
 
 
  from Jules: many if not most cure researchers now have doubts that eradication is going to happen, so attention and hope appears to have turned to "functional cure" which means keeping HIV at bay to the extent that perhaps ARTs could be discontinued and viral suppression could be maintained. Combining an immune modulator, a vaccine is a current new direction and there were several reports - see below - on this approach at CROI and several recent reports in the News. Still more recently, early this year a new study effort was announced to look at combining 2 or 3 antibodies and to combine antibodies with an immune based therapy TLR9 http://www.natap.org/2016/newsUpdates/011317_05.htm and a compilation report of several new research efforts http://www.natap.org/2017/HIV/020117_01.htm
 
Aging and comorbidities is perhaps the major concern in HIV with 80% now in the US with HIV over 40-45 years old, 50% over 50 and 20% over 60 in major cities including NY, SF, Boston, Atlanta and Florida. Older aging HIV+ very often have 3-6 comorbidities and are taking 8-12 c-medications in addition to ART. Concerns are increasing about the affects with disability increasing along with worsening frailty, gait, mobility, depression, housing & long term housing concerns. Increasingly older HIV+ are experiencing falls & consequent fractures as osteoporosos rates / bone disease is worse in HIV+ and worsens with age. Cognitive impairment & frailty are very much associated with this as well as a history of drug use particularly heroin & cocaine, IDU. In WIHS women these problems have been reported and highlighted.
 
At CROI there was a lot of attention to viral suppression in the USA, before getting too elated that viral suppression rates are so grist take a look, perhaps in some cities in some patient populations viral suppression rates are pretty good but success in this area overall is questionable:
 
CROI: LONGITUDINAL VIRAL TRAJECTORY AMONG WOMEN IN THE WOMEN'S INTERAGENCY HIV STUDY - (02/26/17)
 
CROI: CDC - HIV Incidence, Prevalence and Undiagnosed Infections in Men Who Have Sex With Men - HIV incidence decreased among all transmission categories except MSM - (02/26/17) Viral Suppression in NYC, NYS, and LA - (02/26/17)
 
CROI: Ending HIV Epidemic in NYC - Plan/Strategy IF YOU CAN MAKE IT THERE: ENDING THE HIV EPIDEMIC IN NEW YORK - (02/26/17)
 
-------------------------------------------
 
CROI: New HIV Drugs at CROI / CROI Antiretroviral Treatment Summary / Long Acting HIV Therapies - (03/31/17)
 
from Jules: There are 20 reports here on new HIV drugs including 15 reports on long acting new HIV drugs. Nonetheless, safety and tolerability remain issues. Long term safety and toxicity are associated with ARTs, HIV drugs. The discussion always comes up: do we need new HIV drugs, there are so many - the answer is a resounding YES. Despite the large number of presentations at CROi of new HIV drugs and despite that many comment the pipeline is full - NO, we continue to have essentially only protease inhibitors, NNRTIs and integrase inhibitors for most treatment scenarios - WE NEED new classes of HIV drugs IF they are safer and less toxic, that is what is missing. So I would not call the pipeline "flush" - at CROI we have new NNRTI, new PI, new integrase inhibitor, but the only new class and its in very early development is a capsid inhibitor and granted it looks interesting because its also potentially a long acting therapy. GRANTED, ViiV now has the BMS attachment inhibitor and acquired the BMS maturation inhibitor, but we are waiting for the attachment but the maturation inhibitor was discontinued due to "gastrointestinal intolerability and treatment-emergent drug resistance". In the Viiv acquisition of new BMS drugs they also acquired a unique long acting with multiple modes of action drug called Combinectin, previously BMS986197 and now GSK3732394, "a biologic with 3 independent and synergistic modes of HIV entry inhibition that could potentially be self-administered as a long-acting subcutaneous injection, a projected half-life of GSK3732394 of ∼40 hours", here is the latest report from Glasgow 2016 http://www.natap.org/2016/GLASGOW/GLASGOW_27.htm So what is the long term safety and adverse effects profile for the GSK attachment inhibitor? here is early short term safety data http://www.natap.org/2014/IDSA/IDSA_65.htm - The potential adverse effects and toxicities associated with the currently used classes of HIV drugs - NNRTIs, protease, integrase - include increased risks associated with aging related affects like cognitive, brain or neurologic adverse effects, increasing risk factors for cardiovascular disease & adverse metabolic effects including diabetes, potential bone and kidney adverse effects, and of course lipodystrophy: lipoatrophy and/or increased VAT belly fat which increase risk for heart disease, brain & cognitive disorders - even with new ARTs including integrase inhibitors a significant percent of patients from a study comparing raltegravir to a protease inhibitors darunavir/r and atazanavir/r 16%-18% of study participants experienced >10% limb fat loss and 6-8% 20% limb fat loss, and 29%-33%% experienced VAT belly fat gain, of note baseline viral load over 100,000 was associated with much higher fat changes in VAT & SAT, presented at CROI 2015 by Grace McComsey (ACTG5260s) http://www.natap.org/2015/CROI/croi_149.htm
 
CROI Summary 2017: Antiretroviral treatment - where we are now / New HIV Drugs & Treatments - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/06/17)
 
CROI: Efficacy and Safety of Switching to E/C/F/TAF in Virologically Suppressed Women - (02/26/17)
 
CROI: Significant Efficacy and Long-term Safety Difference With TAF-Based STR in NaÏve Adults - (02/16/17)
 
CROI: Long-term Safety and Efficacy of CAB and RPV as 2-Drug Oral Maintenance Therapy - (02/18/17)
 
A Phase 2 Open-Label Trial of Antibody UB-421 Monotherapy as a Substitute for HAART - (03/06/17)
 
---------------------------
 
Adolescents, Children, Neonates, During Pregnancy
 
CROI: Dolutegravir Based cART in Vertically-HIV-1-Infected Adolescents in Real-Life Setting - (02/24/17)
 
CROI: DOLUTEGRAVIR PHARMACOKINETICS, SAFETY AND EFFICACY IN HIV+ CHILDREN 2 TO <6 YEARS OLD - (02/23/17)
 
CROI: IMPAACT P1110: RALTEGRAVIR PHARMACOKINETICS AND SAFETY IN HIV-1 EXPOSED NEONATES: DOSE-FINDING STUDY - (03/02/17)
 
CROI: Pharmacokinetics, Safety, and Efficacy of Atazanavir or Darunavir With Cobicistat in Adolescents (12 to <18 years of age) - - (04/18/17)
 
CROI: PHARMACOKINETICS OF RILPIVIRINE AFTER SWITCHING FROM EFAVIRENZ IN ADOLESCENTS - - (04/18/17)
 
CROI: Substantially Lower Rilpivirine Plasma Concentrations during Pregnancy - - (04/17/17)
 
----------------------
 
Aging
 
CROI: CROI: Neurocognitive Disorders - Neurologic, Brain, Cognitive Impairment - - (04/10/17)
 
CROI: Blood Brain Barrier function, ART neuroactivity and risk of CSF HIV escape / BBB Permeability & Neurocognitive Performance in HIV+ - - (04/12/17)
 
---------------
 
EXPERT Reports
 
  • Cardiovascular Update from CROI 2017 - by Priscilla Hsue MD Professor of Medicine, UCSF - (05/16/17)
     
  • Impressions of CROI 2017 - written by- Pablo Tebas, MD University of Pennsylvania - (03/01/17)
     
    CROI Summary 2017: Antiretroviral treatment - where we are now / New HIV Drugs & Treatments - Joseph J. Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/06/17)
     
    Frailty, Bones, and Vitamin D: CROI 2017 - Todd T. Brown, MD, PhD Professor of Medicine and Epidemiology Johns Hopkins University - (04/06/17)
     
    An Increased Rate of Fracture Occurs a Decade Earlier in HIV+ Compared to HIV- men in the Multicenter AIDS Cohort Study (MACS) - (04/11/17)
     
    CROI: Frailty Status and Risk of Falls in HIV-Infected Older Adults in the ACTG A5322 Study - (03/29/17)
     
    CROI: HIV Infection and the Occurrence of Medically Significant Falls: Accelerated or Accentuated Aging? - - (04/06/17)
     
    CROI: Antiretroviral-induced Bone Loss is Durably Suppressed by A Single Dose of Zoledronic Acid - - (04/05/17)
     
    CROI 2017: Better Living with HIV Infection - written by - David Alain Wohl, MD - The University of North Carolina at Chapel Hill (03/01/17)
     
    HIV Prevention at CROI 2017 Conference on Retroviruses and Opportunistic Infections - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/23/17)
     
    The Kidney at CROI 2017 - written by - Christina Wyatt MD - Associate Professor, Medicine/ Nephrology Icahn School of Medicine at Mount Sinai New York, NY (03/01/17)
     
    CROI: Summary from CROI 2017 for viral Hepatitis HCV - elimination on its way: dream or emerging reality? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/22/17)
     
    CROI: CROI 2017 HCV/HBV Reports - - (04/05/17)
     
    CROI: TDF TO PREVENT PERINATAL HEPATITIS B VIRUS TRANSMISSION: A RANDOMIZED TRIAL (ITAP) - (03/22/17)
     
    CROI: CROI: Neurocognitive Disorders - Neurologic, Brain, Cognitive Impairment - - (04/10/17)
     
    CROI:MRS Measures Associate with Impaired Neuropsychological Performance in Acute HIV - (03/29/17)
     
    --------------------------
     
    RESISTANCE
     
    CROI: Low HIV-1 Resistance in Subjects Using Darunavir Once-daily Regimens Across Studies - - (04/17/17)
     
    CROI: Emergence of Integrase Resistance Mutations During Initial Therapy with TDF/FTC/DTG - (03/27/17)
     
    CROI: HIV Integrase Genotypic Testing and Resistance in the United States-9 U.S. Jurisdictions - (02/22/17)
     
    CROI: LOW PREVALENCE OF HIV DRUG RESISTANCE WITH MODERN AGENTS - (03/06/17)
     
    CROI: INCREASED PERSISTENCE OF INITIAL ART WITH INSTI-CONTAINING REGIMENS - (03/06/17)
     
    CROI: Resistance emergence in macaques administered Cabotegravir long-acting (CAB LA) during acute infection - (03/20/17)
     
    --------------------------
     
    Aging, Comorbidities
     
    CROI: CROI: Neurocognitive Disorders - Neurologic, Brain, Cognitive Impairment - - (04/10/17)
     
    CROI: Effect of cobicistat on tenofovir plasma concentrations: a cross-sectional study - (03/02/17)
     
    CROI: EXERCISE, OXIDATIVE STRESS AND FIBRINOLYTIC FUNCTION IN HIV-1 INFECTED ADULTS - - (04/17/17) regular exercise is an effective intervention strategy for improving endothelial fibrinoltyic function in ART0treated HIV-1 seropositve adults due to at least in part reduced oxidative stress
     
    CROI: BIOMARKERS OF AGEING IN HIV-POSITIVE INDIVIDUALS AND MATCHED CONTROLS: 8 years greater biologic age in HIV+ - (02/24/17)....... CROI: Biological-vs-Chronological Age Difference Significantly Greater With HIV - (03/08/17)
     
    CROI: Association of Inflammation and Coagulation with Clinical Risk in the START Trial ...... - (03/06/17)....This analysis did show that patients that deferred therapy tended to have higher IL-6 & D-Dimer, markers for CVD & comorbidities, but they did not compare the benefit of 500CD4 vs 900 CD4. I say 900 CD4 is definitely more protective thab 500 yet even at 900 CD4 inflammation markers will be higher, thus the only protective thing to do is EXERCISE!!! I am going to gym RIGHT NOW !....higher inflammation (IL-6) markers & coagulation markers were found as a risk for cardiovascular disease, AUDS & non AIDS events in both the immediate & deferred groups in START. Regardng IL-6 and CVD risk those who started earlier HAART (with over 500 CD4) had less risk vs those that deferred treatment.....inflammation is associated with serious non-AIDS events (comorbidities), AIDS & AIDS-death / inflammation persists despite low or high CD4 count, higher CD4 is associated with lower inflammation & less risk for comorbidities, non-AIDS events
     
    CROI: Physical Function and Inflammation in Older HIV-Infected Men - (03/16/17)
    ....Aging with HIV infection is often characterized by chronic inflammation, multimorbidity, and frailty distinguished in part by decreased physical function. The mean (SD) age was 54.5 (7.3) years and 80% were African American race. This is a cross-sectional study of 177 HIV+ men enrolled in the Veterans Aging Cohort Study (VACS) without prior diagnosis of cardiovascular disease. Decreased ambulatory function and poor self-reported function are associated with elevated levels of biomarkers of inflammation in HIV+ older men. We previously found in older HIV+ that the six-minute walk distance (6-MWD) correlates with cardiopulmonary fitness and lung function and further, that the survey-based physical health composite score (PCS) predicts mortality independently of comorbidity. Our current objective is to better understand the relationship between physical function and inflammation by comparing the association of the 6-MWD and the PCS with a panel of biomarkers of inflammation.our study contributes to a growing literature suggesting thatinflammatory processes may play a greater role among those aging with HIV.
     
    CROI: TREND IN MULTIMORBIDITY AMONG HIV+ ADULTS IN CLINICAL CARE IN THE US - (03/29/17)....In NA-ACCORD from 200-2009. Multi-comorbidity prevalence has increased in HIV+ in care; challenges in care become more complex. Unadjusted increase in prevalence of multiple comorbodities triples from 40-49 to >60 age; from jules: this is outdated, 7 years old, I am not sure the patient population in NA-ACCORD, at least that reflected in this poster captures very well the numbers of comorbidities as Figure 1 shows just 6% of study population has 3 comorbidities but that 6% is in the overall population including all age groups, the analysis does not report what percent over 50 or over 60 have 3 or mor comorbidities.
     
    >61 age associated with having 3 to 6 comorbidities in HOPS with IDUs having most comorbidities......CROI: Non-AIDS Illness Burden Differs by Sex, Race, and Insurance Type in Aging HIV+ Adults - HOPS - Number of Comorbidities Double from 45 to 60 Years Old/Blacks Disproportionately Affected - (02/26/17)....This HOPS analysis runs through 2015. After 60 years old 4 is the average number of comorbidities HIV+ have, 1 during 18-40, 2 during 40-50, 3 at 50-60 & 4 when over 60.... from 41-50 to >60 there is a doubling in comorbidities......psych & depression remain relatively high through all age groups including 18-40, over 50% have psych or depression diagnosis.....Blacks have higher comorbidities and compared to other groups increased even more after 60 years old.....Patient using Public payers have higher comorbidities rates
     
    CROI: CROI: Neurocognitive Disorders - Neurologic, Brain, Cognitive Impairment - - (04/10/17)
     
    CROI: Blood Brain Barrier function, ART neuroactivity and risk of CSF HIV escape / BBB Permeability & Neurocognitive Performance in HIV+ - - (04/12/17)
     
    CROI: Persistent Immune Activation Despite ART: The "Die is Cast" Before ART Initiation - (02/16/17)....Higher levels of inflammation and activation before ART were associated with higher levels during ART, indicating that immunologic events that occurred well before ART initiation had long-lasting effects despite sustained virologic suppression (i.e., "the die is cast" before ART initiation). .....Pre ART: Higher inflammation and T cell activation correlated with higher plasma HIV RNA On-ART levels of HIV, inflammation, activation and cycling correlate best with pre-ART levels: higher levels on ART associated with higher levels before ART Suggests "the die is cast": immunologic and virologic effects occurring before ART initiation have long-lasting effects despite sustained virology suppression Interventions that reduce inflammation or activation may have limited effects on HIV persistence Need to understand host & viral factors that affect virologic, immunologic and inflammatory "set points" on ART
     
    CROI: Antiretroviral-induced Bone Loss is Durably Suppressed by A Single Dose of Zoledronic Acid - - (04/05/17)
     
    CROI: Monoclonal Antibody to IL-1beta Cuts Arterial Inflammation in 10 HIV Patients - (02/22/17)
     
    CROI: APPLES - The Australian Positive & Peers Longevity Evaluation Study - (02/18/17) .....In this sample of HIV+ and HIV- MSM over the age of 55 years, we see an increased prevalence of some self-reported comorbidities including thrombosis, diabetes, heart disease, and neuropathy in HIV+ MSM compared to HIV- MSM. HIV+ MSM were more likely to have ever smoked, and engage in recreational drug use, however, HIV- MSM report more current smoking and alcohol use. These data suggest that older HIV+ MSM indeed experience some non-communicable diseases at higher rates compared to HIV- MSM of similar age, despite smoking and other traditional risk factors.This study underscores the importance of an appropriate HIV- control group for more accurate evaluation of the risk and attribution of age-related comorbidities in HIV+ people.
     
    CROI: CEREBRAL SMALL-VESSEL DISEASE IN HIV-INFECTED PATIENTS WELL CONTROLLED ON CART - (02/28/17) ....CSVD was detected in 51.5% of PLWHIV and 36.4% of HNC. Prevalence of cerebral small-vessel disease was 52% in well controlled HIV+ group over 50 years age with an ORa of 2.3 (1.5-3.6) compared with HIV-unifected. CD4 nadir <200 was a risk factor, so was classical risk factors age & hypertension.
     
    Cost of noninfectious comorbidities in patients with HIV - Cost of HIV CARE Increases 5 fold Due to Cost for Comorbidities from <40 to >60 - (03/23/17)
     
    CROI: Factors associated with rapid eGFR decline while receiving TDF and/or ATV - (03/02/17)
     
    CROI: Changes In Liver Steatosis After Switching Efavirenz To Raltegravir: The STERAL Study - (03/29/17)
     
    CROI: Raltegravir Switch and Biomarkers of Liver Steatosis and Metabolic Syndrome in Women - (03/29/17)
     
    CROI: FATTY LIVER DISEASE: A GROWING CONCERN - - (04/12/17) a plenary talk by noted fatty liver expert Rohit Loomba from UCSD
     
    CROI: Changes in Liver Fibrosis and Steatosis in HIV Mono-Infected patients over 24 months - 50% have fatty liver at average age of 46 - (03/28/17)
     
    CROI: LIVER STEATOSIS AND FIBROSIS IN AT-RISK EUROPEAN HIV-MONOINFECTED PATIENTS - 64% with steatosis among those who had elevated LFTs and/or metabolic syndrome and/or lipodystrophy - (03/28/17)
     
    CROI: Hyperbilirubinemia prevents cardiovascular disease for HIV+ and HIV-individuals - (02/20/17)
     
    Oral Session Thursday: INFLAMMATION AND AGE-RELATED COMPLICATIONS - 4 studies (1) Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors (2) Smoking Cessation & Impact on Cancers & Lung Cancer Risks in HIV+ (3) New CVD Anti-Inflammatory in Pilot Study in HIV+ (4) Hyperbillirubinemia Prevents CVD Risk - (02/20/17)
     
    CROI: Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D Study - (02/22/17) Smoking cessation reduces smoking unrelated cancers & smoking related cancers excluding lung cancer, but over 5 years followup there is not a statistically significant reduction in lung cancers but a non statistical reduction - "Although lung cancer incidence falls in the general population when people quit smoking [2], it remained elevated for several years after cessation in this HIV group. [ 10 years after quitting: The lung cancer death rate is about half that of a person who is still smoking. (US Surgeon General's Report, 2010 see link below) - Oncolink. Abramson Cancer Center of the University of Pennsylvania. Former smokers and cancer risk.
     
    CROI: Association between Cardiovascular Disease & Contemporarily Used Protease Inhibitors - D:A:D (02/22/17) ....All D:A:D participants 49,709, 35,711in prospective followup; CVD N=1,157 (3.2%) - stroke N=379 MI; angioplasty N=459 bypass; endarterectomy N=15 sudden cardiac death
     
    CROI: Darunavir/r Use and Incident Chronic Kidney Disease in HIV-positive Persons - study found increased CKD risk with ATV but not with Darunavir - D:A:D Cohort - (02/20/17)
     
    CROI: EPICARDIAL FAT, IMMUNE ACTIVATION, AND CORONARY PLAQUE AMONG HIV+ AND HIV- WOMEN - (02/18/17)
     
    CROI: The Effect of ART on Inflammation, Coagulation and Vascular Injury in START..... "Immediate ART led to reductions at 8 months of 12-21% in D-dimer, IL-6, SAA, sICAM and sVCAM levels compared with deferral of ART.".....likely reducing risk for comorbidities - (03/06/17)
     
    Modifiable Risk Factors for MIs - CROI: Impact of smoking, hypertension, and cholesterol on myocardial infarction in HIV-infected adults...."hypertension, cholesterol & smoking are very strong drivers of MIs in HIV+" - (03/10/17) ...43% of MI cases could be avoided if these individuals did not have elevated total cholesterol. in the NA-ACCORD there were 347 MIs mostly in age groups 40-59; prominent risk factors included smoking, elevated Total Cholesterol, treated hypertension, diabetes, stage 4 chronic kidney disease, CD4 <200, HCV
     
    CROI: COPD Markers Linked to Tripled Mortality Risk in People With HIV - (03/30/17)
     
    CROI: Cancer risk among HIV-infected people in the U.S. during the modern treatment era - (03/06/17)
     
    CROI: CANCER INCIDENCE AMONG PERSONS ON MODERN SUPPRESSIVE ANTIRETROVIRAL THERAPY, 2000-12 - (03/06/17)
     
    CROI:Exhausted T-cells and Inflammatory Monocytes are Linked to Brain Atrophy in HIV - (03/10/17)
     
    Aging & HIV - an unaddressed time-bomb waiting to explode - slide presentation by Jules Levin, NATAP - (03/14/17)
     
    CROI: Psychiatric Disorders Observed in HIV+ Patients Using 6 Common 3rd Agents in OPERA - (02/20/17)
     
    CROI: Neuropsychiatric Adverse Events Associated With Integrase Strand Transfer Inhibitors - (02/20/17)
     
    CROI: Discontinuation of DTG, EVG/c, and RAL due to toxicity in a prospective cohort - (02/20/17)
     
    CROI: EFFECT OF DOLUTEGRAVIR PLASMA CONCENTRATION ON CENTRAL NERVOUS SYSTEM SIDE EFFECTS - (02/23/17)
     
    CROI: STEADY-STATE PHARMACOKINETICS OF DOLUTEGRAVIR IN PEOPLE LIVING WITH HIV OVER THE AGE OF 60 YEARS - (02/23/17)
     
    CROI: Increased dolutegravir exposure in HIV patients switched from ritonavir to cobicistat - (02/23/17)
     
    CROI: Crushing of dolutegravir combination tablets increases dolutegravir exposure - (03/02/17)
     
    CROI: Telomere length: neurocognitive biomarker in HIV-1-infected subjects - (03/02/17)
     
    CROI: Leukocyte Telomere Attrition is Rapid Following HIV but not HCV Seroconversion - (03/02/17)
     
    CROI: Novel Imaging Strategy Shows High-Level Aortic CD206+ Macrophage Infiltration in HIV ......CVD risk / inflammation - (03/08/17)
     
    CROI:
    CHANGES IN THE ORAL MICROBIOME WITH ART INITIATION / Microbiome Affects of Low Baseline CD4/High Viral Load - (03/08/17)....."Constrained correspondence analysis demonstrates that there are statistically significant differences in the microbiota of samples with low CD4 and high viral load.....participants with baseline CD4<200 and high viral load >100,000 exhibited differences in dominant taxa, demonstrating more Capnocytophaga ....Capnocytophagahas been associated with periodontal disease, which has been seen in HIV+ participants with advanced immune deficiency. These shifts are partly reversed by 24 wksof ART .....Conclusions: We demonstrated no overall significant shift in the salivary microbiome after 24 wks of ART. However, advanced HIV disease is associated with differences in the microbiome, which may be contributing to inflammation and periodontal disease in this population."
     
    CROI: Predictors of Severe Weight/Body Mass Index Gain Following Antiretroviral Initiation - - (04/18/17)
     
    Aging of HIV-Infected: an explosive and underestimated phenomena being ignored, needs attention - special support services for patients & clinics needed-lack of federal/state response - HCV too - (04/04/17)
     
    --------------------------
     
    CURE
     
    Impressions of CROI 2017 - written by- Pablo Tebas, MD University of Pennsylvania - (03/01/17)
     
    IAS Cure Report: CROI 2017: Basic Science Review Mario Stevenson, PhD
     
    CROI:
    Identification of Latency Reversing Agents (LRAs) Active in Diverse Primary T-cell Models of HIV Latency - (02/18/17)
     
    CROI: A Bi-Specific Approach for Targeting IMRs in HIV-1 Latency - (03/02/17)
     
    CROI: 288 Day Drug-Free Remission From HIV Rebound by Allogeneic PBSCT - (02/16/17)
     
    CROI: INTEGRASE AND PROTEASE INHIBITOR CONCENTRATIONS IN LYMPH NODE AND GUT MUCOSAL TISSUE - (03/29/17)
     
    CROI: TLR9 AGONIST TRIGGERS POTENT INTESTINAL ANTIVIRAL RESPONSE IN HIV+ INDIVIDUALS ON ART - (02/23/17)
     
    CROI: TLR7 Agonist GS-9620 (Vesatolimod) Increases Immune-Mediated Clearance of HIV-Infected Cells
     
    CROI: TLR7 Agonist GS-986 Markedly Activates T & B Cells From ART-suppressed Donors - (02/23/17)
     
    CROI: TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Complete Viral Remission - (02/23/17)
     
    CROI: DEVELOPMENT OF A PKC AGONIST DERIVED FROM INGENOL FOR HIV LATENCY DISRUPTION IN VIVO - - (04/12/17)
     
    Two plenaries in HIV Cure - CROI: The Emerging Potential for HIV Cure for Infants, Children, and Adults - and - ADVANCES IN CELLULAR THERAPY IN CANCER AND HIV - (02/22/17)
     
    CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses - (03/16/17)
     
    ------------------------
     
    PrEP
     
    HIV Prevention at CROI 2017 Conference on Retroviruses and Opportunistic Infections - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/23/17)...there is a long report on PrEP at CROI in this prevention report from CROI
     
    CROI: Acute infection with a wild-type HIV-1 virus in a PrEP user with high TDF levels - (02/20/17) ...FIRST case of infection with wild-type HIV-1 in a person with documented supposedly protective intracellular levels of TFV-DF.
     
    CROI: The Challenges of Translating PrEP Interest into Uptake among Young Black MSM in Atlanta, GA - (03/10/17)
     
    CROI: On Demand Post-Exposure Prophylaxis with Doxycycline for MSM Enrolled in a PrEP Trial - (02/16/17) including an Oral Plenary on - ANTIBIOTIC PROPHYLAXIS FOR STIs: PROMISES OR PERILS
     
    CROI: Bacterial Vaginosis Does Not Affect Oral TDF/FTC PrEP Efficacy - (03/10/17)
     
    CROI: IMPACT OF VAGINAL MICROBIOTA ON GENITAL TISSUE AND PLASMA CONCENTRATIONS OF TENOFOVIR - (03/10/17)
     
    CROI: Older Age Associated with both Adherence and Renal Decline in the PrEP Demo Project - (03/10/17)
     
    CROI: Bone Changes With TDF-containing and Non-TDF-containing (maraviroc) Prep in U.S. Men and Women - (03/10/17)
     
    CROI: Brief Behavioral Intervention Increases PrEP Drug Levels in a Real World Setting - (03/10/17)
     
    CROI: STD PARTNER SERVICES TO MONITOR AND PROMOTE PREP USE AMONG MEN WHO HAVE SEX WITH MEN - (03/20/17)
     
    CROI: Concordant Population-level Increases in PrEP Found with Novel Public Health Methods - (03/20/17)
     
    CROI: Text Messaging is Associated with Improved Retention in a Clinic-based PrEP Program - (03/20/17)
     
    New PrEP Cascade Methods Find 1 in 10 Benefit from PrEP - Uptake of HIV Pre-Exposure Prophylaxis (PrEP) in a National Cohort of Gay and Bisexual Men in the United States - (02/14/17)
     
    CROI 2017 - Conference on Retroviruses and Opportunistic Infections (CROI) February 13-16, 2017, Seattle WA